NO944913L - Fremgangsmåte for å inhibere LDL-oksydasjon og arteriosclerosis - Google Patents

Fremgangsmåte for å inhibere LDL-oksydasjon og arteriosclerosis

Info

Publication number
NO944913L
NO944913L NO944913A NO944913A NO944913L NO 944913 L NO944913 L NO 944913L NO 944913 A NO944913 A NO 944913A NO 944913 A NO944913 A NO 944913A NO 944913 L NO944913 L NO 944913L
Authority
NO
Norway
Prior art keywords
arteriosclerosis
ldl oxidation
chem
inhibiting ldl
inhibiting
Prior art date
Application number
NO944913A
Other languages
English (en)
Other versions
NO313083B1 (no
NO944913D0 (no
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944913D0 publication Critical patent/NO944913D0/no
Publication of NO944913L publication Critical patent/NO944913L/no
Publication of NO313083B1 publication Critical patent/NO313083B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Liquid Crystal Substances (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19944913A 1993-12-21 1994-12-19 Anvendelse av forbindelser for fremstilling av preparat for å inhibere LDL-oksydasjon og arteriosclerosis NO313083B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17060693A 1993-12-21 1993-12-21

Publications (3)

Publication Number Publication Date
NO944913D0 NO944913D0 (no) 1994-12-19
NO944913L true NO944913L (no) 1995-06-22
NO313083B1 NO313083B1 (no) 2002-08-12

Family

ID=22620568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19944913A NO313083B1 (no) 1993-12-21 1994-12-19 Anvendelse av forbindelser for fremstilling av preparat for å inhibere LDL-oksydasjon og arteriosclerosis

Country Status (20)

Country Link
EP (3) EP1095654B1 (no)
JP (1) JPH07196498A (no)
KR (1) KR950016722A (no)
CN (1) CN1095663C (no)
AT (3) ATE254459T1 (no)
AU (1) AU698389B2 (no)
CA (1) CA2138508A1 (no)
CZ (1) CZ286365B6 (no)
DE (3) DE69433348T2 (no)
DK (2) DK1095654T3 (no)
ES (3) ES2163425T3 (no)
HU (1) HUT71476A (no)
IL (1) IL112034A (no)
NO (1) NO313083B1 (no)
NZ (1) NZ270162A (no)
PT (3) PT1095654E (no)
RU (1) RU2127592C1 (no)
TW (1) TW427902B (no)
UA (1) UA39941C2 (no)
ZA (1) ZA9410091B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
DE69622472T2 (de) * 1995-06-07 2003-02-06 Lilly Co Eli Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
EP2070535B1 (en) 1998-08-24 2015-07-08 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates
RU2464794C1 (ru) * 2011-10-25 2012-10-27 Канапья Табылдыевич Шагиев Состав для производства кисломолочного продукта "курт"
CN103768601A (zh) * 2012-10-22 2014-05-07 中国科学院上海生命科学研究院 抑制micro-RNA155用于预防和治疗动脉粥样硬化的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
ES2215270T3 (es) 2004-10-01
CZ286365B6 (cs) 2000-03-15
DE69428882T2 (de) 2002-04-25
NO313083B1 (no) 2002-08-12
UA39941C2 (uk) 2001-07-16
ES2163425T3 (es) 2002-02-01
EP0664121B1 (en) 2001-10-31
EP0664121A1 (en) 1995-07-26
ATE260104T1 (de) 2004-03-15
AU8156394A (en) 1995-06-29
ES2210089T3 (es) 2004-07-01
IL112034A (en) 1999-03-12
KR950016722A (ko) 1995-07-20
NZ270162A (en) 1997-06-24
RU94045270A (ru) 1996-10-20
CZ320494A3 (en) 1995-09-13
EP0963756A3 (en) 1999-12-22
DK0664121T3 (da) 2001-12-03
PT664121E (pt) 2002-03-28
DE69433578T2 (de) 2004-12-16
CA2138508A1 (en) 1995-06-22
NO944913D0 (no) 1994-12-19
PT963756E (pt) 2004-06-30
ATE207749T1 (de) 2001-11-15
HU9403660D0 (en) 1995-02-28
TW427902B (en) 2001-04-01
DK1095654T3 (da) 2004-03-15
HUT71476A (en) 1995-11-28
EP1095654A2 (en) 2001-05-02
CN1095663C (zh) 2002-12-11
EP1095654A3 (en) 2001-06-13
JPH07196498A (ja) 1995-08-01
EP0963756A2 (en) 1999-12-15
IL112034A0 (en) 1995-03-15
EP1095654B1 (en) 2003-11-19
DE69433578D1 (de) 2004-04-01
ZA9410091B (en) 1996-06-19
RU2127592C1 (ru) 1999-03-20
DE69433348T2 (de) 2004-08-26
CN1108090A (zh) 1995-09-13
DE69433348D1 (de) 2003-12-24
ATE254459T1 (de) 2003-12-15
EP0963756B1 (en) 2004-02-25
PT1095654E (pt) 2004-04-30
AU698389B2 (en) 1998-10-29
DE69428882D1 (de) 2001-12-06

Similar Documents

Publication Publication Date Title
NO944913D0 (no) Fremgangsmåte for å inhibere LDL-oksydasjon og arteriosclerosis
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
NO943878L (no) Hemming av uterinfibrose
DK0659416T3 (da) Inhibering af seborE og acne
AU7578694A (en) Methods for treating resistant neoplasms
NO943873D0 (no) Hemming av bruskdegradering

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees